CHRDL1 and benign prostatic hyperplasia: have identified CHRDL1, NEFH, TAGLN, and SYNM as novel diagnostic biomarkers for BPH and PCa, which aid in early diagnosis, treatment, and assessment of immunotherapeutic responses.